Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for Bradmer Pharmaceuticals in a report released on Monday, March 31st. Cantor Fitzgerald analyst B. Knoblauch now anticipates that the company will post earnings of ($1.06) per share for the year, down from their previous forecast of $3.35. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock.
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- How to Profit From Value Investing
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- Dividend Payout Ratio Calculator
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
